ZyVersa Therapeutics, Inc.
ZVSA
$0.6794
-$0.0306-4.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.89M | 1.17M | 1.83M | 2.04M | 2.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.14M | 1.29M | 2.27M | 2.75M | 2.83M |
| Operating Income | -2.14M | -1.29M | -2.27M | -2.75M | -2.83M |
| Income Before Tax | -2.26M | -1.42M | -2.40M | -2.75M | -2.83M |
| Income Tax Expenses | -- | -3.00K | -- | 9.70K | -- |
| Earnings from Continuing Operations | -2.26M | -1.42M | -2.40M | -2.76M | -2.83M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.26M | -1.42M | -2.40M | -2.76M | -2.83M |
| EBIT | -2.14M | -1.29M | -2.27M | -2.75M | -2.83M |
| EBITDA | -2.14M | -1.29M | -2.27M | -2.75M | -2.82M |
| EPS Basic | -0.73 | -0.71 | -2.43 | -3.31 | -4.53 |
| Normalized Basic EPS | -0.45 | -0.45 | -1.52 | -2.06 | -2.83 |
| EPS Diluted | -0.73 | -0.71 | -2.43 | -3.31 | -4.53 |
| Normalized Diluted EPS | -0.45 | -0.45 | -1.52 | -2.06 | -2.83 |
| Average Basic Shares Outstanding | 3.11M | 1.99M | 988.40K | 834.90K | 623.60K |
| Average Diluted Shares Outstanding | 3.11M | 1.99M | 988.40K | 834.90K | 623.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |